for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Antares Pharma Inc

ATRS.OQ

Latest Trade

4.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.54

 - 

5.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.86
Open
--
Volume
--
3M AVG Volume
35.05
Today's High
--
Today's Low
--
52 Week High
5.12
52 Week Low
2.54
Shares Out (MIL)
163.23
Market Cap (MIL)
770.43
Forward P/E
-118.00
Dividend (Yield %)
--

Latest Developments

More

Antares Pharma Reports Third Quarter 2019 Operating And Financial Results

Antares Pharma Reports Second Quarter 2019 Operating And Financial Results

Antares Pharma Reports Q1 Loss Per Share Of $0.03

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Antares Pharma Inc

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Industry

Medical Equipment & Supplies

Contact Info

SUITE 300, 100 PRINCETON SOUTH

+1.609.3593020

https://www.antarespharma.com/

Executive Leadership

Leonard S. Jacob

Independent Chairman of the Board

Robert F. Apple

President, Chief Executive Officer, Director

Fred M. Powell

Chief Financial Officer, Executive Vice President

Peter J. Graham

Executive Vice President, Chief Compliance Officer - Human Resources, General Counsel, Corporate Secretary

James Patrick Tursi

Executive Vice President, Head of Research and Development, Chief Medical Officer

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.160

2017

-0.110

2018

-0.040

2019(E)

-0.040
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.35
Price To Book (MRQ)
17.34
Price To Cash Flow (TTM)
343.33
Total Debt To Equity (MRQ)
90.67
LT Debt To Equity (MRQ)
90.67
Return on Investment (TTM)
-0.85
Return on Equity (TTM)
-0.60

Latest News

Latest News

BRIEF-Idorsia In Partnership With Antares To Develop Drug-Device Product For Selatogrel

* ENTERS INTO A COLLABORATION WITH ANTARES FOR DEVELOPMENT OF A NOVEL SELF-ADMINISTERED DRUG-DEVICE PRODUCT FOR SELATOGREL

Antares Pharma's testosterone drug gets FDA approval

The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected.

Antares Pharma's testosterone drug gets FDA approval

The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's drug to treat low testosterone levels in men, the company said, nearly a year after rejecting the injection.

MEDIA-Russia to supply U.S. with new rocket engines - Kommersant

* Russian engine maker Energomash has signed a new contract to supply four RD-181 rocket engines to U.S. aerospace firm Orbital ATK by 2021 for its Antares rocket, the Kommersant newspaper wrote on Tuesday.

BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04

* ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

BRIEF-Antares Pharma Q4 Loss Per Share $0.02

* ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted

* Antares pharma receives complete response letter from the fda for Xyosted

BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

* Antares Pharma Inc - anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017

BRIEF-Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

* Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals

BRIEF-Antares Pharma entered sales agreement with cowen and co to offer, sell shares of its common stock, par value $0.01/share- SEC Filing

* Antares Pharma-on Aug 11,entered sales agreement with Cowen and Company under which co may offer, sell shares of its common stock,par value $0.01/share

BRIEF-Antares Pharma Q2 loss per share $0.02

* Antares pharma reports second quarter 2017 operating and financial results

BRIEF-Antares Pharma announces debt financing from Hercules Capital

* Antares Pharma announces debt financing from Hercules Capital

BRIEF-Antares Pharma files $200 mln mixed shelf

* Files for mixed shelf of up to $200 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Antares Pharma reports Q1 loss per share $0.03

* Antares Pharma reports first quarter 2017 operating and financial results

BRIEF-Antares Pharma Q4 loss per share $0.03

* Antares pharma reports fourth quarter and full year 2016 operating and financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up